Summary: The Alzheimer’s Tau Platform (ATP) trial is the first large-scale study specifically designed to evaluate combination therapies that target both amyloid plaques and tau tangles at once. Uniquely, ATP screens and treats people who are asymptomatic but show early biological indicators of Alzheimer’s on advanced imaging, with the aim of interrupting the disease process before irreversible cognitive decline occurs.
Key Facts
- Dual-target strategy: Existing approved therapies focus on amyloid, which can be present for many years without causing symptoms. Clinical decline typically accelerates after tau begins to accumulate. ATP will test whether addressing both proteins together delivers superior protection against progression.
- Adaptive platform model: ATP uses a flexible infrastructure that allows new therapies from different companies to be added over time. This adaptive approach reduces costs and time compared with one-drug, one-trial models and enables parallel testing of multiple combinations.
- Early intervention in asymptomatic participants: The trial actively enrolls people who do not yet show memory problems but who have biomarker evidence of Alzheimer’s-related pathology. Treating at this stage aims to prevent or delay the onset of clinical symptoms.
- All participants receive active therapy during the study: To encourage participation and lower the burden on volunteers, everyone enrolled will receive at least one active treatment at some point in the trial.
- Two-step therapeutic design:
- Phase 1 (first 6 months): Participants receive either placebo or donanemab, a monoclonal antibody approved to clear amyloid plaques and slow early decline.
- Phase 2 (next 24 months): Participants transition to a tau-targeting therapy, either alone or combined with donanemab, to evaluate the impact of sustained dual-protein intervention.
- First tau therapy in the platform: The initial tau-directed agent entering ATP is AADvac1, an active immunotherapy designed to stimulate the patient’s immune system to recognize and remove pathological tau aggregates.
Source: UCSF
Screening begins: The first two people with early or asymptomatic Alzheimer’s will be screened this week for a national trial led by UC San Francisco. The study aims to enroll up to 825 participants at multiple sites across the United States.
ATP is notable for including people who have no overt symptoms but do have Alzheimer’s-consistent biomarkers on brain imaging. By enrolling these individuals and offering active treatment to all participants, the trial seeks to evaluate whether early, combination therapy can alter the underlying disease trajectory.
To date, FDA-approved Alzheimer’s therapies have targeted amyloid, a protein that forms plaques and disrupts neuronal signaling. Tau, which forms neurofibrillary tangles, is closely linked to the onset of cognitive decline. Researchers involved with ATP emphasize that amyloid can accumulate quietly for a decade or more, while clinical symptoms commonly appear after tau begins to spread.
“Many people have amyloid plaques in their brain for over a decade but don’t develop symptoms until tau starts to accumulate,” said co-principal investigator Adam Boxer, MD, PhD, of the UCSF Fein Memory and Aging Center. “This trial will test whether treating both amyloid and tau at the earliest signs of tau buildup will work better than targeting either protein alone.”
Funded by the National Institutes of Health (R01AG078457), the Alzheimer’s Tau Platform aims to accelerate development of tau-directed therapies while lowering costs and burden for patients. ATP will also generate a large repository of clinical data and biological samples to support future research into disease mechanisms and biomarkers.
In Phase 1, participants receive either placebo or donanemab for six months. In Phase 2, they receive a tau-directed treatment—starting with AADvac1—either alone or in combination with donanemab for two years. AADvac1 is an active vaccine approach that trains the immune system to recognize and clear misfolded tau proteins that form toxic tangles.
The trial is co-led by Keith Johnson, MD, of Massachusetts General Hospital and Harvard Medical School. ATP is open to people aged 50 to 80 who either have mild cognitive impairment or are asymptomatic but meet amyloid and tau biomarker criteria. Participants must agree to regular assessments, including advanced brain imaging and blood-based tests.
Key Questions Answered:
A: Waiting until memory loss becomes evident often means waiting until substantial, irreversible brain damage has occurred. Amyloid can build up silently for years; significant cognitive decline typically correlates with the later spread of tau. By identifying and treating individuals who are biologically at risk but still asymptomatic, investigators hope to prevent or slow downstream neurodegeneration.
A: Traditional trials typically evaluate a single drug from a single sponsor and then conclude, dismantling study infrastructure. A platform trial keeps infrastructure in place, allowing researchers to add new drugs and combinations over time. This reduces overhead, shortens timelines, lowers participant burden, and lets multiple treatment strategies be tested efficiently under a common protocol.
A: AADvac1 is an active immunotherapy that functions like a vaccine. Instead of supplying manufactured antibodies, it stimulates the patient’s immune system to recognize the misfolded forms of tau that form neurotoxic tangles. The immune response then produces targeted defenses that can help clear pathological tau before it causes widespread neuronal damage.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The underlying journal paper was reviewed in full by editorial staff.
- Additional context was added by the reporting team to clarify the trial design and aims.
About this Alzheimer’s disease research news
Author: Suzanne Leigh
Source: UCSF
Contact: Suzanne Leigh – UCSF
Image: Image credit: Neuroscience News